Literature DB >> 9560094

Botulinum toxin decreases salivation from canine submandibular glands.

C M Shaari1, B L Wu, H F Biller, S K Chuang, I Sanders.   

Abstract

The objective of this study was to determine whether botulinum toxin types A and D reduced the production of saliva from the submandibular glands of 18 dogs. The left submandibular glands of 8 dogs were injected with increasing doses of botulinum type A toxin (range 10 to 70 units), and the left glands of 10 dogs were injected with botulinum type D toxin (50 or 100 units). The right gland of each dog was injected with equivalent volumes of saline solution to serve as control. Six days after the injection, the lingual nerve was electrically stimulated for 10 minutes (3 mAmp, 20 Hz). The resulting volume of saliva was collected and weighed. Overall, the glands injected with types A or D toxin produced significantly less saliva than comparable glands injected with saline solution. Six of 8 dogs injected with type A toxin showed a significant decrease in saliva production (range 10.1% to 19.2%, one-sided p value = 0.0375) when compared with the controls. Nine of 10 dogs injected with type D toxin demonstrated a highly significant reduction in saliva production (total average decrease = 60%, two-sided pvalue = 0.001) when compared with the controls. We concluded that intraglandular injections of botulinum toxin types A and D significantly reduced the production of saliva from canine submandibular glands. The potential applications of intraglandular injections of botulinum toxin are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560094     DOI: 10.1177/019459989811800404

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  7 in total

Review 1.  The treatment of cervical dystonia with botulinum toxins.

Authors:  C L Comella
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 2.  Evidence for the effectiveness of botulinum toxin for sialorrhoea.

Authors:  D D Truong; R Bhidayasiri
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

3.  Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation.

Authors:  David J Keegan; Gerd Geerling; John P Lee; Glen Blake; J Richard Collin; Gordon T Plant
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 4.  [Treatment of sialorrhea with botulinum toxin: an overview].

Authors:  J Hagenah; K G Kahl; S Steinlechner; R Lencer; C Klein
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

5.  Histopathological and radiological investigations of the influence of botulinum toxin on the submandibular gland of the rat.

Authors:  Berna Uslu Coskun; Hayati Savk; Esin Derin Cicek; Tulay Basak; Muzaffer Basak; Burhan Dadas
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-07       Impact factor: 2.503

6.  Blood-to-saliva glucose time lag in sedated healthy dogs.

Authors:  Antonia Ioannou; Heidi Phillips; Stephanie Keating; Anne Barger; Nicolas Lopez-Villalobos; Macy Wilson; Alyssa Dillonaire; Rebecca Silveston-Keith; Tamas D Ambrisko; Arnon Gal
Journal:  J Vet Diagn Invest       Date:  2021-07-23       Impact factor: 1.569

7.  Botulinum toxin in gastric submucosa reduces stimulated HCl production in rats.

Authors:  Matteo Runfola; Simone Rossi; Simona Panunzi; Pier Luigi Spada; Daniele Gui
Journal:  BMC Gastroenterol       Date:  2003-09-10       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.